Uveal melanoma is a rare type of eye cancer characterized by blurred vision or dark spots on the iris. Eye exam is one of the options used in the diagnosis of uveal melanoma. Surgery, radiation therapy, photocoagulation, and thermotherapy are used in the treatment of unveal melanoma. Nivolumab-an immunotherapeutic drug that has been shown to help people with uveal melanoma by improving the patient's overall immunity. In addition, other similar drugs that are being studied for the treatment of uveal melanoma include a combination of Ipilimumab and Nivolumab and Selumetinib. Selumetinib is a targeted drug that is known to slow the growth of ocular melanoma.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the uveal melanoma market.
Top Impacting Factors
- Surge in demand for targeted drug therapies for rare disease treatment, increase in cases of genetic disorder, rise in geriatric population, surge in cases of over exposure to sunlight, and increase in cases of intraocular melanoma are the major factors that drive the growth of market.
- In addition, surge in adoption of advance cancer treatment drug therapies, increase in R & D activities to develop cancer treatment products, rise in number of clinical trials for launch of novel melanoma treatment drugs, increase in awareness regarding treatment & diagnosis of cancer, and technological advancement in therapeutics are some factors that fuel the growth of market.
- However, lack of eye imaging technologies and ignorance related diagnosis of eye in underdeveloped countries hinder the growth of market.
- Contrarily, favourable reimbursement policies and support from government for regulatory approval present new pathways in the industry.
Market Trends
Rise in R&D Activities for Launch of Novel Treatment Procedures
In 2018, Aura Bioscience Company engaged with to launch targeted therapy to destroy cancer cells using viral capsid conjugates. This novel treatment can be used in treatment of choroidal melanoma and oculary tumor.
In 2018, Immunocore Limited released phase 1 and phase 2 dose escalation trial of their product IMCgp100 for treatment of metastatic unveal melanoma treatment. This drug can be the most effective treatment method for unveal melanoma.
Key Benefits of the Report
- This study presents the analytical depiction of uveal melanoma market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Uveal Melanoma Market Report
- Which are the leading players active in the uveal melanoma market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "uveal melanoma"?
- What is "uveal melanoma" market prediction in the future?
- Who are the leading global players in the "uveal melanoma" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "uveal melanoma" market report?
Uveal Melanoma Market, by Drug Type Report Highlights
| Aspects | Details |
 By Drug Type |
|
 By Therapy Type |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | F. Hoffmann-La Roche Ltd, Bayer, Astra Zeneca plc, Merck, Pfizer, Inc., Novartis AG, Bristol-Myers Squibb Company, Spectrum Pharmaceuticals, Inc., Amgen, Eli Lilly & Co. |
Loading Table Of Content...
